ArticleClinical rheumatology2026
What are risk factors for relapse in relapsing polychondritis? A retrospective study.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveThis retrospective study aims to investigate the risk factors for relapse in relapsing polychondritis (RP).
methodsPatients diagnosed with RP and treated at Shanxi Bethune Hospital from October 2011 to December 2024 were considered. Those who met the 1979 Damiani classification criteria were selected and categorized into relapse and non-relapse groups. The Cox proportional hazards model and Kaplan-Meier survival curve analysis were used to identify the risk factors associated with RP relapse.
resultsThe study enrolled a total of 28 patients with RP. Airway and nasal involvement were more common in the relapse group (n = 13) than in the non-relapse group (n = 15) (75.0% vs 25.0%, p = 0.020; 53.8% vs 13.3%, p = 0.042, respectively). Pre-treatment RPDAI scores, C-reactive protein (CRP) levels, and IgG levels were higher in the relapse group (30.3 ± 11.9 vs 20.5 ± 9.9, p = 0.024; 96.3 ± 81.9 vs 22.8 ± 15.8 mg/L, p = 0.007; 15.9 ± 6.6 vs 11.0 ± 2.5 g/L, p = 0.020, respectively). Univariate analysis of the Cox proportional hazards model suggests that airway involvement, CRP levels and IgG levels before treatment are significantly associated with the risk of relapse (HR 3.787, 95% CI 1.160 - 12.359, p = 0.027; HR 9.707, 95% CI 2.575 - 36.594, p = 0.001; HR 5.515, 95% CI 1.780 - 17.084, p = 0.003; respectively). When compared to non-airway involvement group (n = 15), airway involvement group (n = 13) showed higher RPDAI scores, CRP levels, and initial prednisolone dosage before treatment (30[22.5-33.0] vs 20[9-30], p = 0.030; 60[34.5-128.9] vs 28[6-46] mg/L, p = 0.020; 60[40-60]vs 30[15-50] mg/d, p = 0.020, respectively).
conclusionsAirway involvement, CRP levels and IgG levels before treatment may be risk factors for relapse in RP patients, and patients with airway involvement often require higher doses of corticosteroids. Key Points • The study indicates that airway involvement, CRP levels and IgG levels before treatment are risk factors for recurrence in relapsing polychondritis, and when airway involvement is present, higher initial doses of corticosteroids are used.
Indexed as
Identifiers
41413312What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.